SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Bio climbs higher on the BSE

06 Mar 2012 Evaluate

Panacea Bio is currently trading at Rs. 75.95, up by 0.70 points or 0.93% from its previous closing of Rs. 75.25 on the BSE.

The scrip opened at Rs. 74.05 and has touched a high and low of Rs. 77.50 and Rs. 74.05 respectively. So far 2786 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 199.45 on 26-Apr-2011 and a 52 week low of Rs. 70.00 on 30-Dec-2011.

Last one week high and low of the scrip stood at Rs. 79.00 and Rs. 74.05 respectively. The current market cap of the company is Rs. 465.20 crore.

The promoters holding in the company stood at 74.85% while Institutions and Non-Institutions held 3.18% and 21.97% respectively.

Drug firm, Panacea Biotec has withdrawn its oral polio vaccine from the World Health Organisation’s (WHO) list of pre-qualified vaccines stating the facility where the vaccine is being manufactured needs further corrective actions. The company withdrew the vaccine despite undertaking several measures regarding refurbishment of the facility and strengthening of QMS from September to December, 2011.

A team from WHO has audited the company’s manufacturing facility at Okhla in the capital from January 3 to February 1, to assess the quality management systems (QMS) applied to production and control of oral polio vaccines (OPV). WHO reported that OPV produced by the company will no longer be supplied through United Nations (UN) agencies.

The company, however, will continue to supply OPVs which were produced prior to the production halt in September 2011, as monitoring and testing of these lots confirm compliance with quality specifications.

Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

344.60 -13.40 (-3.74%)
20-Apr-2026 14:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.20
Dr. Reddys Lab 1235.00
Cipla 1232.20
Zydus Lifesciences 936.50
Lupin 2331.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×